CGTX
Cognition·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Hanging Man
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CGTX
Cognition Therapeutics, Inc.
A biopharmaceutical company focused on developing innovative therapeutics for neurological and psychiatric disorders
2500 Westchester Ave., Purchase, NY 10577
--
Cognition Therapeutics, Inc., was incorporated under the laws of the State of Delaware on August 21, 2007. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapies for age-related degenerative and central nervous system diseases (CNS) and the retina. There are currently limited therapies available to treat diseases, and there are no approved therapies or treatments for many diseases. The company's goal is to develop disease-modifying treatments for patients with degenerative diseases by initially leveraging its expertise in β-2 (SIGMA-2) receptors.
Company Financials
EPS
CGTX has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.09, beating expectations. The chart below visualizes how CGTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
